Drug Sponsors

Epizyme earns $4M in milestones from GSK for novel HMT therapeutics

Thursday, October 4, 2012 11:52 AM

Epizyme, a pharmaceutical company focused personalized therapeutics for cancer, received a $4 million milestone payments from collaborator GlaxoSmithKline based on the achievement of pre-clinical milestones.

More... »

BMS, Sanofi restructure alliance agreement

Thursday, October 4, 2012 10:36 AM

Global biopharmaceutical company Bristol-Myers Squibb and global healthcare company Sanofi have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.

More... »

Sanofi to acquire Genfar

Thursday, October 4, 2012 10:04 AM

Global healthcare company Sanofi has signed an agreement to acquire Genfar, a pharmaceuticals manufacturer headquartered in Bogota, Colombia. With this acquisition, Sanofi will expand its portfolio of affordable pharmaceuticals in Latin America.

More... »

Janssen to develop, commercialize Astellas’ ASP015K for immunologic diseases

Wednesday, October 3, 2012 09:52 AM

Janssen Biotech and Astellas Pharma have formed a license agreement whereby Janssen gains the exclusive right to develop and commercialize ASP015K, an Astellas compound, worldwide except for Japan.

More... »

BioInvent focuses its business, reduces staff

Tuesday, October 2, 2012 01:54 PM

Sweden-based BioInvent International has decided to focus its operations with the aim of achieving self-financing of the business before external costs for future new clinical studies. Its development of proprietary antibody drugs will concentrate primarily on developing new cancer drugs, resulting in a clear indication focus. The company currently has five agreements with major companies based on products from the antibody library, n-CoDeR. It will increase the efforts to create new n‑CoDeR agreements for clinical programs and continue to develop existing partnerships.

More... »

Merck Serono: 40% of Geneva staff have job prospects

Tuesday, October 2, 2012 01:50 PM

Merck Serono has provided an update on the redeployment of its Geneva-based staff, 100 days after announcing its decision to close the site. As of Sept. 28, job prospects have been clarified for more than 500 employees, or 40% of Geneva-based employees:

More... »

Evotec, Bayer form multi-target alliance to fight endometriosis

Monday, October 1, 2012 02:57 PM

Evotec, a German drug discovery alliance and development partnership company, and Bayer have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.

More... »

Cardium acquires To Go Brands

Monday, October 1, 2012 10:24 AM

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company based in San Diego, announced that its MedPodium operating unit has acquired the assets, business and product portfolio of San Diego-based To Go Brands, a developer of nutraceutical powder mixes, supplements and chews to support healthy lifestyles, to support the expansion of Cardium's health sciences nutraceutical brand platform.

More... »

NeuroCog Trials receives $1.2M NIMH grant

Monday, October 1, 2012 09:09 AM

NeuroCog Trials, a Durham, N.C.-based cognitive services provider for the clinical trials industry, has received a 2012 phase II grant from the Small Business Innovation Research (SBIR) program from the National Institute of Mental Health (NIMH), for the validation and commercialization of its Virtual Reality Functional Capacity Assessment Tool (VRFCAT).

More... »

Medtronic to acquire China Kanghui Holdings

Friday, September 28, 2012 02:32 PM

Medtronic, a global medical technology company based in Minneapolis, Minn., has agreed to acquire China Kanghui Holdings for approximately $816 million in cash ($30.75 per American depository share). The total value of the transaction, net of Kanghui's cash, is expected to be approximately $755 million.

More... »